Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 Asian Penny Stocks With Market Caps Below US$8B

In This Article:

Amidst global market turbulence, Asian markets have shown resilience, with Japan's stock indices experiencing modest gains and China's markets buoyed by stimulus hopes. In such an environment, investors often look for opportunities in smaller or less-established companies that may offer value and growth potential. Penny stocks, though sometimes perceived as relics of earlier trading days, continue to attract attention when backed by strong financials. In this article, we explore three Asian penny stocks that stand out for their financial strength and potential for long-term success.

Top 10 Penny Stocks In Asia

Name

Share Price

Market Cap

Financial Health Rating

Interlink Telecom (SET:ITEL)

THB1.42

THB1.97B

★★★★☆☆

Chumporn Palm Oil Industry (SET:CPI)

THB2.82

THB1.78B

★★★★★★

Beng Kuang Marine (SGX:BEZ)

SGD0.22

SGD43.83M

★★★★★★

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD2.37

SGD9.36B

★★★★★☆

Jiumaojiu International Holdings (SEHK:9922)

HK$3.34

HK$4.67B

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$4.16

HK$47.68B

★★★★★★

Lever Style (SEHK:1346)

HK$1.31

HK$831.57M

★★★★★★

China Lilang (SEHK:1234)

HK$3.83

HK$4.59B

★★★★★☆

China Zheshang Bank (SEHK:2016)

HK$2.53

HK$82.33B

★★★★★★

Xiamen Hexing Packaging Printing (SZSE:002228)

CN¥3.11

CN¥3.6B

★★★★★★

Click here to see the full list of 1,150 stocks from our Asian Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

CSPC Pharmaceutical Group

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CSPC Pharmaceutical Group Limited is an investment holding company involved in the research, development, manufacture, and sale of pharmaceutical products across China, other Asian regions, North America, Europe, and internationally with a market cap of approximately HK$57.40 billion.

Operations: CSPC Pharmaceutical Group generates revenue from several segments, including Finished Drugs (CN¥24.97 billion), Bulk Products - Vitamin C (CN¥1.91 billion), Functional Food and Others (CN¥2.02 billion), and Bulk Products - Antibiotics (CN¥1.82 billion).

Market Cap: HK$57.4B

CSPC Pharmaceutical Group's recent endeavors highlight its dynamic approach in the pharmaceutical sector, notably with the Breakthrough Therapy Designation for JSKN003, a promising anti-HER2 biparatopic ADC. This designation could expedite clinical development and approval processes, potentially addressing unmet needs in ovarian cancer treatment. Despite a challenging year with decreased profits due to price cuts and competitive pressures, CSPC remains financially robust with short-term assets exceeding liabilities and debt well-covered by cash flow. However, negative earnings growth and management inexperience may pose challenges as it navigates market dynamics while expanding its innovative drug pipeline.